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Abstract 
Chronic inflammation contributes to changes in vascular function in a range of vascular 
diseases. Whether these vascular changes in function are nerve-mediated remains unknown. 
Sympathetic nerve-mediated responses in isolated tail arteries of rats in an experimentally 
induced chronic inflammatory state were examined. Electrical field stimulations between 1.25 
and 40 Hz resulted in frequency-dependent contractions sensitive to tetrodotoxin. Neurogenic 
contractions in blood vessels of experimental animals were significantly greater compared to 
those of control animals. Alpha1-adrenoceptor antagonists significantly inhibited contractile 
responses at lower frequencies of stimulation (1.25 – 5 Hz) in blood vessels of experimental rats 
compared to controls. Alpha2-adrenoceptor antagonism had no effect on electric field-evoked 
vasoconstrictions in experimental and control animals. Inhibition of neuronal reuptake by 
cocaine comparably enhanced field-stimulated responses in blood vessels of experimental and 
control animals. Furthermore, the expression of α1- and α2-adrenoceptors was different in the 
endothelium of blood vessels of treated animals compared to control animals. The observation 
of enhanced neurogenic contraction in blood vessels of animals in a chronic state of 
inflammation may be attributed to alterations in responsiveness and/or distribution of post-
junctional α1-adrenoceptors. 
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1. Introduction 
1.1. The circulatory system 
 The circulatory system is a “collection of organs” which permits the circulation of blood 
and the transport of oxygen and nutrients to body organs, and the removal of carbon dioxide 
and metabolic wastes away from tissues. The transport modality by this system contributes to 
homeostasis within the body through the constant exchange of nutrients and metabolic 
materials (Sherwood et al., 2013). The mammalian circulatory system itself consists of the heart 
as the pump, blood as the transport medium and the blood vessels as the passageway for 
circulating fluid (i.e. blood); which circulates in a closed circuit between the systemic and 
pulmonary circulations. This network originates from the heart travelling through the 
vasculature, arteries, arterioles, capillaries, venules and veins, and back to the heart through 
both the pulmonary and systemic vasculatures (Sherwood et al., 2013).  
1.1.1. The vasculature 
 The vascular (blood vessel) component of the circulatory system provides the network 
and the route for the transport of needed material and the removal of waste from cells and 
tissues. It consists of arteries and veins which make up the macrocirculation, and the arterioles, 
capillaries and venules which constitute the microcirculation. These blood vessels differ in their 
constitutive wall layers, comprising endothelial cells, smooth muscle cells and connective 
tissue. The difference in constitutive wall tissue reflects the function of the individual layer. The 
innermost layer known as the tunica intima consists of a one-cell thick layer of endothelial cells 
(the endothelium) and the subendothelial space. The middle layer called the tunica media, is 
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the thickest layer and is composed of smooth muscle cells. Finally, the outermost layer, the 
tunica adventitia is composed mainly of fibrous and elastic connective tissue as well as 
sympathetic nerve endings (Figure 1). Each of these layers serves a distinct physiological 
function depending on the type of blood vessel (Sherwood et al., 2013). 
1.1.2. Vascular physiology 
 The innermost cell layer of endothelial cells is the major exchange site for nutrients. This 
function is possible due to the single cell nature of this layer allowing for semi-permeability and 
increased surface area at the capillary level (Pries and Kuebler, 2006). For this reason, the 
capillaries which constitute only the endothelium are the major site of nutrient and waste 
exchange for the tissues (Pries and Kuebler, 2006; Sherwood et al., 2013). The smooth muscle 
cell layer, adjacent to the endothelium, allows non-capillary and venule blood vessels to 
constrict or dilate by contracting and relaxing the smooth muscle, respectively. Vascular 
smooth muscle cells have specialized receptors (e.g. adrenoceptors) which play an important 
role in the sympathetic nerve function in blood vessels. Contraction of the muscle layer by 
sympathetic nerves alters the radius (and lumen) of the vessel and the corresponding flow of 
blood. This contractile capability of the smooth muscle layer and its ability to vary vessel lumen 
constitutes the regulation of vascular tone and resistance to flow (Perez, 2005; Zacharia et al., 
2013; Tank and Lee Wong, 2015). The smooth cell layer varies in thickness depending on the 
blood vessel. For example, arteries have a thicker smooth muscle layer compared to capillaries 
and veins. This permits arteries such as the abdominal aorta to sustain high pressures from the 
pumping heart and at the same time regulate blood pressure; the reason arteries are 
considered pressure vessels (Sherwood et al., 2013). Finally, the outermost connective tissue 
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also varies in elastic and fibrous tissue and nerve tissues, depending on the type of blood 
vessel. For example, main arteries are highly elastic, allowing them to distend under high 
pressures, whereas arterioles are highly innervated (with little or no elastic tissues) allowing for 
direct regulation of resistance through smooth muscle-induced changes in lumen radius. For 
this reason, arterioles are considered resistance vessels (Sherwood et al., 2013).  
Generally, modifications of the structure, morphology, and/or function of vascular 
tissues have been associated with altered blood vessel responses in pathophysiological states. 
In clinical settings, vascular diseases caused by conditions such as atherosclerosis are initiated 
by endothelial cell dysfunction and may be precipitated by the inflammatory response (Togan 
et al., 2015; Park and Park, 2015; Ross and Glomset, 1973).  
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Fig 1. Light micrograph of the cross-section of a tail artery from a saline-treated rat. Micrograph 
shows arteries consisting of three morphologically distinct layers: tunica adventitia, media and 
intima. The thicker smooth muscle layer houses the contractile machinery of the vasculature. 
Image taken under transmitted light at 20X magnification. 
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1.2. Sympathetic nervous system and nerve function 
 The sympathetic nervous system (SNS) is broadly defined as a branch of the autonomic 
nervous system (ANS), responsible for regulating unconscious physiological responses in the 
body. It acts complementary to the parasympathetic branch to maintain homeostasis. Early 
studies revealed that two kinds of neurons, the pre- and postganglionic neurons, are involved in 
neuronal transmission in the SNS. The shorter pre-ganglionic neurons originating from T1-L2 
levels of the spinal cord synapse at the sympathetic ganglia, whereas the longer post-ganglionic 
neurons carry signals from the ganglion to the effector tissues or organs in the entire body 
(Drake et al., 2005). Stimulation of the sympathetic chain transmits signals via the action of 
neurotransmitters released from nerve endings.  Pre-ganglionic neurons release acetylcholine 
(ACh) which activates the acetylcholine (nicotinic) receptors present on the post-ganglionic 
neurons. In response to ACh activation, post-ganglionic neurons release norepinephrine, which 
interact predominantly with adrenoceptors of the target tissues in the peripheral systems (Tank 
and Lee Wong, 2015). 
 Decades of experimental work have provided evidence of the sympathetic nervous 
system’s central role in the regulation of multiple homeostatic mechanisms. Sympathetic nerve 
fibers supply the internal organs, including the heart, blood vessels, lungs, intestines, genitals, 
kidneys, salivary and digestive glands and pupils (Drake et al., 2005). Stimulation of the 
sympathetic nerves has been associated with initiating the “fight and flight” response. In the 
heart, sympathetic outflow of norepinephrine accelerates the heart rate. In other systems, 
stimulation of the sympathetic nerves causes constriction of associated blood vessels, 
relaxation of bronchioles, dilation of pupils, increased sodium and water reabsorption in the 
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kidneys, reduced peristaltic movement in the gut and inhibition of digestive and salivary gland 
secretions. Hence, the sympathetic nervous system is able to effect physiological changes 
through the activation of specialized receptors in target organs.   
1.2.1. Adrenoceptors 
Adrenoceptors form a class of membrane G protein-coupled receptors (GPCR). 
Adrenoceptors mediate the physiological effects of the catecholamines norepinephrine and 
epinephrine in the central and peripheral systems in the body. Norepinephrine and epinephrine 
are both important in the homeostasis of various systems within the body. Hence, the 
adrenoceptors to which they bind are widely distributed throughout the body to promote their 
regulatory functions. Stimulation of the sympathetic nervous system and neurotransmitter 
binding to these receptors activates the receptor complex causing physiological changes. 
Activation of the adrenoceptors by neurotransmitter released from the sympathetic nervous 
system results in various responses depending on the systems involved. In the brain for 
example, activation of adrenoceptors has been involved in learning and memory (Shakhawat et 
al., 2012), bronchodilation in the lungs (Paolillo et al., 2013), increased heart rate in cardiac 
tissue (Capote et al., 2015), regulation of tubular sodium reabsorption in the kidneys via renin 
release (Mansley et al., 2014), and vascular tone (Wegener et al., 2014; Zacharia et al., 2013). In 
the cardiovascular system in particular, adrenoceptors mediate constriction and dilation of the 
blood vessels via contraction and relaxation of the smooth muscle cells. Diameter changes in 
the vasculature affecting the total peripheral resistance are very important in the regulation of 
organ blood supply (perfusion) and contribute to the maintenance of vascular tone. This 
regulation also plays an important role in the metabolic regulation of blood flow to organs to 
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meet metabolic demands (e.g. during physical exercise) and autoregulatory mechanisms in the 
brain to ensure constant blood supply at all times (Sherwood et al., 2013).  
1.2.2. Classification of adrenoceptor subtypes 
In the adrenoceptor family, the two main receptor groups are the alpha (α) 
adrenoceptors and the beta (β) adrenoceptors.  All the same, 20th century ligand binding 
studies elucidated the structure-function characteristics of the receptors which allowed 
investigators to classify them in subtypes based on their interactions with agonists and 
antagonists. Under the alpha receptor category, researchers have classified two sub-categories 
which are the alpha1 and alpha2 adrenoceptors. There is also evidence of multiple receptor 
subtypes of the main adrenoceptor types. For example, within the alpha1 type, alpha-1A, -1B 
and -1D subtypes have been identified. Similarly, alpha-2A, -2B and -2C subtypes have also 
been identified under the alpha2-adrenoceptor type. In contrast, subtypes of the beta-
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Fig 2. Classification of adrenoceptors, their G-protein and effectors (and physiological effects). 
PLC, phospholipase C; PKC, protein kinase C; DAG, diacylglycerol; AC, adenylyl cyclase; cAMP, 
cyclic adenosine-3’, 5’-monophosphate; +, activation; -, inhibition; ↑, increase; ↓, decrease. 
(Adapted from Garland and Angus, 1996). 
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1.2.3. Structure of adrenoceptors 
 Adrenoceptors, being GPCR’s, are integral membrane-spanning proteins that consist of 
seven transmembrane (TM) domains (Yarden et al., 1986; Pierce et al., 2002). These 
transmembrane bundles form pockets stabilized by amino acid residues on the helices (figure 
3). Furthermore, the structure of the receptors is very important in determining ligand-binding 
and signal transduction pathways, regulated by the adrenoceptors (Perez, 2006).     
 Molecular modelling and mutagenesis studies have provided experimental evidence of 
four structural components involved in the receptor-ligand interactions (Finch et al., 2005). 
Basically, these experiments conclude that binding of the catecholamine functional groups with 
the receptor transmembrane (TM) functional pockets form the basis of agonist and antagonist 
stereo-selectivity of the ligands.  Interactions of the catecholamine amino group and the helix 
carboxylate group create ionic interactions between the ligand and the helix residues of the 
receptors (Finch et al., 2005; Bockaert et al., 2003). Secondly, interaction between the catechol 
meta- and para-hydroxyl groups with the serine residues of the TM helix create hydrogen 
bonding between the agonist and the receptor putative transmembrane helix. Interaction 
between the phenyl group and the aromatic groups of the helix residues constitute aromatic-
aromatic interactions for agonist binding. These interactions are all essential for ligand-receptor 
binding and define the affinity of an agonist for the receptor. Studies on receptor gene 
mutations have also demonstrated that changes in TM helix or ligand residue affect the 
receptor-ligand interaction and hence the activation of the receptor (Strader et al., 1987). 
Mutations of serine molecules from the particular TM domains affect the receptor subtype 
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selectivity and ligand affinity for both alpha- (Gros et al., 1998) and beta-adrenoceptors (Cavali 
et al., 1996).  
 In addition, one other type of interaction, the hydrogen bonding between the chiral 
benzene β-hydroxyl of norepinephrine and the residues of the TM helix VI determines the 
stereoselectivity for adrenergic agonists and antagonists (Finch et al., 2005). Green et al. (1993) 
showed that mutations in the serine residue (T4.56) to isoleucine produced a fourfold reduction 
in the adrenoceptor affinity for epinephrine and norepinephrine. They suggested that the loss 
of binding affinity stemmed from the mutation-induced conformational change which 
prevented the proper functional interaction between the ligand and the receptor. 
Adrenoceptor types and subtypes show ligand selectivity for epinephrine and norepinephrine 
with respect to both ligand affinity and agonist potency.  
Aside from the stereoselective nature of ligand/receptor interactions, there are specific 
ligand-binding residues unique to each receptor type (α and β) that confer receptor selectivity. 
There are ligand-binding residues which are unique to the receptor subtypes that also confer 
subtype selectivity (Hwa et al., 1995). Only two of the over 176 amino residues that constitute a 
receptor TM helix account for the α1A ligand selectivity (Hwa et al., 1995). In addition, receptor 
residues distinguished by their location on the TM segments (I – VII) also confer agonist and 
antagonist specificity. Phenylalanine residues in TM segments IV and V have been found to play 
a role in general α1 agonist-binding (Waugh et al., 2000). In contrast to agonist binding, unique 
residues found on TM segments III – VII have been identified to confer antagonist specificity. 
Waugh et al. (2000) showed that mutations in these residues (TM IV and V) impact the affinity 
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of the agonist phenylephrine on the α1A receptor, but do not affect binding of the antagonist 
prazosin to the same receptor.  
 
Fig 3. Generic representation of an adrenoceptor (seven transmembrane protein) displaying the 
functional interactions between the ligand, epinephrine and the receptor binding sites. From 
Perez (2005).   
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1.2.4. Adrenoceptors and functional effects 
Adrenoceptors play a role in the regulation of many physiological functions including 
those involved in circulatory, metabolic, respiratory and central nervous system homeostasis 
(Medgett and Rajanayagam, 1984). Activation of adrenoceptors has been found to cause an 
increase in heart rate (Suita et al., 2015), dilation of bronchioles in the lungs, decreased 
gastrointestinal movement and blood vessel constriction (Tank et al., 2015; Suita et al., 2015). 
In the mammalian circulatory system, adrenoceptors have the crucial role of mediating vascular 
smooth muscle contraction. Depending on their location, catecholamines activate different 
adrenoceptors and have different physiological effects. For example, the effects of NE in the 
cardiac muscles through the activation of β receptors differ from the activation of these same 
receptors within smooth muscles in the peripheral vasculature. Activation of β adrenoceptors in 
the heart mediate increases in both cardiac rate and contractility, whereas stimulation of β 
adrenoceptors in the peripheral vessels mediate smooth muscle relaxation (Xiang and Kobilka, 
2006).  
Several studies have investigated the effects of the sympathetic neural transmitters in 
adrenoceptor activation (binding) and the mechanisms of receptor action (signaling 
transduction pathways) affecting the physiology of the cardiovascular system. Major categories 
of adrenoceptors have also been differentiated based on the class of G-protein to which they 
bind. Each class of G-protein has been defined based on the structure and function of the alpha 
subunit the TM helix couples (figure 2). In mammals, the alpha adrenoceptor can couple with 
three different alpha subunit types which make up the trimeric G-protein coupling unit, which 
include the G(s), G(q) and G(i) alpha subunits (Hildebrandt, 1997; Albert and Robillard, 2002). 
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Adrenoceptors have been shown to activate pathways specific to the alpha G-protein subunit 
they bind. The functional significance of the G-protein subunit heterogeneity is related to the 
different mechanisms by which the G-proteins transduce the effect of neurotransmitters and 
the cellular changes occurring through the signaling transduction pathways (Hildebrandt, 1997). 
With regards to alpha adrenergic receptors, activation of α1 receptors activates the Gq coupled 
alpha subunit pathway, whereas activation of the α2 activates the Gi coupled alpha subunit 
pathway, each of which activate different downstream signaling pathways (Figure 2). 
Stimulation of the α1/Gq receptor G-protein complex activates the enzyme phospholipase C 
(PLC) in a cascade of events which catalyze the hydrolysis of phosphatidylinositol 4, 5-
bisphosphate causing intracellular Ca2+ release and the activation of protein kinases (e.g. PKC). 
Physiologically, this produces depolarization of vascular smooth muscle and vasoconstriction 
(Mori et al., 2015). In contrast, stimulation of the α2/Gi receptor G-protein complex mediates 
two functional effects: first, the inhibition of adenylyl cyclase (and its catalytic conversion of 
ATP to cAMP) which decreases intracellular Ca2+ release in vascular smooth muscle cells, 
causing vasoconstriction (Cavarape et al., 2003). Secondly, a negative feedback loop is activated 
through the presynaptic α2/Gi complex which inhibits (and/or regulates) calcium release within 
the sympathetic nerve endings, inhibiting the release of neurotransmitter from the vesicles 
(Hernandez et al., 2007). The functional significance of the pre-junctional α2 activation is to 
decrease the neurotransmitter release and regulate sympathetic-mediated vascular tone 
(Hernandez et al., 2007). Figure 2 summarizes the adrenoceptor subtype classification and their 
mechanisms of action.  
1.2.5. Pharmacology of adrenoceptors and their functional effects 
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Several techniques have been very useful in characterizing the function of adrenoceptor 
types and subtypes in vascular pharmacology. Pharmacological differences in vasoconstrictor 
responses to sympathetic nerve stimulation have well demonstrated the role of the 
adrenoceptors in vessels. Studies using selective receptor blocking drugs have suggested the 
predominant involvement of post-junctional α1 adrenoceptors in the nerve-mediated 
vasoconstrictor responses since the responses were seldom affected by selective α2 blockers. In 
proximal segments of the rat tail artery, Medgett and Langer (1984) found significant reduction 
in neurogenic-mediated vasoconstrictor responses due to the selective α1 antagonist prazosin. 
However, these responses were not significantly affected by the selective α2 antagonist 
idazoxan (Medgett and Langer, 1984; Medgett and Rajanayagam, 1984). In rat and porcine 
pulmonary arteries, contractile responses to sympathetic nerve stimulation were significantly 
inhibited by selective α1 antagonists, prazosin and WB4101, as well as the neuronal Na+ channel 
blocker tetrodotoxin (Duggan et al., 2011), whereas cocaine enhanced these contractile 
responses (Duggan et al., 2011). Studies have suggested that the contractile function of VSMC is 
primarily dependent on α1-adrenoceptor activation whereas postganglionic depolarization is 
dependent on α2 activation (Brock et al., 1997; Jobling et al., 1992). The application of other 
molecular techniques including receptor protein-site mutagenesis and transgenic (receptor) 
knock-out studies extend the functional findings of the adrenoceptors of previous 
pharmacological approaches. Targeting the genes responsible for the expression of receptor 
types has also been a valuable approach to determine the physiological responses they affect. 
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1.2.6. Sympathetic innervation of the caudal vasculature 
The main ventral artery in the rat tail is densely innervated with noradrenergic nerve 
plexus (Sittiracha et al. 1987) and this density appears to decrease down the tail, from proximal 
to distal end (Jobling and McLachlan, 1992). For this reason, the proximal segment of the rat tail 
artery has been very instrumental in studies that aim to characterize the function of alpha-
adrenoceptors and provides a unique opportunity to study α-adrenoceptor activation in normal 
and disease states. Studies have demonstrated alpha-adrenoceptors in the rat tail artery are 
responsible for mediating the effects of neuronally released noradrenaline (Tanaka et al., 2004). 
Histochemical studies reveal the abundance of alpha1A and alpha1D adrenoceptor subtypes in 
the proximal segment of the main ventral tail artery in rats (Kamikihara et al., 2007). Similarly, 
other histochemical studies have demonstrated the presence of α1-adrenoceptors on the 
vascular smooth muscle of the tail artery in contrast to the α2 receptors which are 
predominantly present on the endothelium of vascular tissues (Kamikihara et al., 2007). These 
findings have been corroborated by physiological studies in control animals revealing the 
functional differences of these alpha receptors. For example, the electrophysiological studies by 
Jobling et al. (1992) demonstrated that contractile responses in rat caudal arteries were 
antagonized by α1 blockers (e.g. prazosin) but not α2 blockers. However, the neuronal alpha 
depolarization (NADs) were only significantly antagonized by the α2 blocker (e.g. idazoxan) but 
not the α1 blockers.   
All the same, there appears to be no data on the effects of inflammation on 
adrenoceptor function and their associated vascular nerve-mediated contractile responses. 
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1.3. Inflammation in the cardiovascular system 
 Inflammation is a protective biological response of tissues in the body to foreign stimuli 
such as pathogens or damaged cells. This biological response, also known as the inflammatory 
response, involves the detection of a wide variety of foreign particles and is characterized by 
signs of swelling due to increased vascular permeability, pain, redness, heat and loss of function 
(Rather, 1971). Controlled inflammation is necessary for immunological function as immune 
regulatory cells are constantly interacting with foreign bodies in the system to regulate pro-
inflammatory effector cells (Jiminez et al., 2015). Hence, the purpose of this response is to 
eliminate the foreign bodies and return functional normality to the system. The inflammatory 
process involves many cells including immune cells (e.g. macrophages, T-cells and neutrophils), 
vascular tissues, and membrane mediators which interact with foreign bodies. Although this 
biological response is normal and beneficial for the organisms in regulating infection and injury, 
excessive and persistent inflammatory response could contribute to a variety of inflammatory 
diseases.  Furthermore, the duration of the inflammation response is also important in 
characterizing vascular diseases associated with chronic inflammation persisting for weeks, 
months or longer, as well as acute episodes only lasting hours mediated by increased 
movement of plasma and leukocytes from blood to the interstitial space (Jimirez et al., 2015). 
1.3.1. The inflammatory response 
The innate and adaptive (humoral) systems constitute the two important lines of 
defense of the immune system (Warrington et al., 2011). Both immune systems, are involved in 
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the detection of foreign particles and the inflammatory response. The innate system is the first 
immunologic and non-specific line of defense and plays an important role in the rapid initiation 
of a response. Here, the presence of a foreign particle is detected by the free circulating 
monocytes and leukocytes. Adaptive immunity, on the other hand is an antigen-dependent and 
antigen-specific response that enables rapid reactivity in the event of pathogen reoccurrence or 
prolonged exposure. In either line of defense, this detection is made possible by adhesion 
molecules, expressed on the surface of leukocytes. These adhesion molecules interact with and 
recognize the particle-associated molecular patterns (PAMPs) displayed on the foreign particles 
and initiate a reaction necessary to trigger the inflammatory response. In vascular tissues, these 
adhesion molecules are expressed on the innermost endothelial cells. Binding to a “stimulus” or 
foreign particle activates the leukocytes in a cascade of events resulting in the release of 
cytokines which modulate the inflammatory process (Warrington et al., 2011). Several studies 
on inflammation have recognized some important pro-inflammatory cytokines involved in the 
cascade for the response in inflammation. Some of these are tumor necrosis factor-alpha (TNF-
α), interferon gamma (IFNγ), interleukine-1, 6 and 8 (Calder, 2006; Dinarello, 1996). Several 
studies have consistently demonstrated a positive correlation between the expression of these 
cytokines and the inflammatory response, in conditions where the expression of such cytokines 
is upregulated during chronic inflammation (Marques-Rocha et al., 2015); the reason they are 
termed pro-inflammatory cytokines and why the expression of these cytokines is used as 
experimental and clinical predictors of inflammation.  
Depending on the location of the inflammatory reaction, the response can be deemed 
localized or systemic. In localized inflammation, the inflammatory process is confined to a 
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certain organ or structure within the body. In systemic inflammation, however, the 
inflammatory reaction is general within the body. In systemic inflammation, the response is not 
confined to any particular tissue but involves the endothelium and other organ systems.  This is 
possible where the stimuli or mediators of the inflammatory response are transmitted through 
the cardiovascular system by way of the circulating blood, affecting other organ systems. 
Essentially, in systemic inflammation, the response is everywhere, and may involve multiple 
organ tissues. All systems and especially the vascular tissues undergo inflammation to the 
existing stimuli. The cascade of events involving the expression of inflammatory markers 
(cytokines) plays an important role to (1) initiate the inflammatory response by activation of the 
innate immune system and (2) link both (innate and adaptive) mechanisms of the immune 
system in mediating the inflammatory response.   
1.3.2. Inflammation and cardiovascular disease 
The presence of foreign particles in blood triggers a controlled (protective) 
inflammatory response by initiating mechanisms in the vascular walls that mediate 
inflammation. Some of these mechanisms involve the expression of adhesion molecules (ICAMS 
and VCAMS) on the endothelial and smooth muscle cell surface, which promotes the 
recruitment of leukocytes, monocytes and macrophages to the sites of inflammation (Brown et 
al., 2001; Hirata et al., 1998). Chronic inflammation has been found to induce vascular 
endothelial and smooth muscle cell remodeling including collagen deposition which 
accentuates the onset of altered vascular function (Lee et al., 2015). In a study to investigate 
leukocyte/monocyte expression after TNF-α infusion in human umbilical vein endothelial cells 
(HUVEC), Pu et al. (2002) demonstrated endothelial cell modifications (i.e. that increased the 
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expression of VCAMs) which altered the cell-to-cell interactions and the function of the 
endothelium. Hence, chronic inflammation has been associated with the development of a 
range of both acute and chronic diseases. Evidence of inflammation in cardiovascular diseases 
is most often characterized by the increased expression of adhesion molecules and endothelial 
cell damage (Collie-Duguid and Wahle, 1996; Hirata et al., 1998) as well as the excessive 
production of pro-inflammatory cytokines (Dinarello, 1996) in the vascular tissue. The 
characteristic increase in blood flow and vascular permeability in states of inflammation also 
allows the increased movement of leukocytes and cytokines across the endothelium into the 
surrounding tissues (Calder, 2006). Such chronic responses cause excessive tissue damage and 
the aggregation of leukocytes and monocytes in surrounding tissues which maintains or 
amplifies the response. Researchers have linked the expression of inflammatory mediators to 
asthma (Henderson, 1992), type 2 diabetes and obesity. Elsewhere, the excessive productions 
of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) occurring during chronic inflammation have 
been implicated in some disease states such as rheumatoid arthritis, acute respiratory 
syndrome, irritable bowel disease, Alzheimer’s, peripheral artery disease (PAD) and 
atherosclerosis (Pande et al., 2014). As such, inflammation is well recognized for its important 
contribution in the pathophysiology of cardiovascular disease. 
The release of these cytokines has been associated with the development of some 
cardiovascular diseases such as atherosclerosis and heart reperfusion injury. In the 
cardiovascular system, the role of the inflammatory processes in the development of vascular 
lesions is well documented. A recent meta-analysis conducted by Zhang et al. (2015) found a 
positive correlation between vascular intima media (endothelial layer) thickness and levels of 
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IL-6 in patients with cardiovascular disease. Similarly, Pande et al. (2014) demonstrated an 
association between TNF-α, a biomarker of systemic inflammation and the occurrence of 
peripheral artery disease. Pande et al. (2014) found significant elevations in the expression of 
the monocyte TNF-α genes in patients with peripheral artery disease; which exerted a negative 
impact on patients’ cardiovascular health. Furthermore, evidence of hyperglycemia-induced 
activation of leukocytes in type 2 diabetic patients and its involvement in vascular damage (de 
Vries et al., 2014) suggests it plays a role in the inflammatory process in conjunction with other 
metabolic defects such as those associated with obesity.   
The role of inflammation in cardiovascular diseases has increased research interest and 
activity in the field of cardiovascular function in those affected. Research in cardiovascular 
function has demonstrated that changes in vascular physiology and function stem from 
inflammation and are responsible in promoting vascular diseases such as atherosclerosis. 
Seemingly, endothelial dysfunction, a characteristic of vascular inflammatory diseases causes 
vascular stiffness and alters the contractility of smooth muscle cells in vascular tissues 
(Huveneers et al., 2015). Leal et al. (2015) found contractile hyper-responsiveness of 
atherosclerotic mice aortic rings to phenylephrine in apolipoprotein- (apoE) treated mice 
compared to the controls. Interestingly, studies assessing vascular changes in hypertensive 
animals have reported similar findings where endothelial dysfunction has been linked with a 
heightened contractile sensitivity and increased sympathetic reactivity (Mori et al., 2015) within 
vascular smooth muscle cells. These therefore, present a link between inflammation, vascular 
tissue (endothelial and smooth muscle cell) dysfunction and cardiovascular disease. 
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1.3.3. Inflammation and effector signaling pathways 
 The involvement of chronic inflammation at the onset and progression of many diseases 
including type-2 diabetes, obesity, atherosclerosis, and asthma is mediated by the expression of 
cytokines and adhesion particles in organ endothelial cells (Marques-Rocha et al., 2015). Pro-
inflammatory mediators play a role in activating immune system cells in plasma and vascular 
tissues. This activation of leukocytes and macrophages dictates a ligand binding relation 
between the chemotactic cytokines and the receptors on the endothelial cells as well as the 
receptors elsewhere in the vascular tissues (Marques-Rocha et al., 2015). Monocytes, 
macrophages and leukocytes express varying types of toll-like receptors (TLRs) that participate 
in cellular activation; and the initiation of a wide spectrum of responses during inflammation 
(Akira et al., 2006; Marques-Rocha et al., 2015). Little is known about the signaling pathways by 
which the inflammatory process (i.e. cytokines) activate the immune cells and maintain the 
inflammatory process. The signaling pathways and regulatory mechanisms involved in vascular 
diseases as a result of chronic inflammation remain incompletely understood.  
Nevertheless, some studies have linked the expression of pro-inflammatory cytokines 
with the activation of certain signaling pathways such as phospholipase C (PLC) and protein 
kinase C (PKC) to the initiation of the inflammatory response in various disease states. Olofsson 
et al. (2006) previously reported the involvement of CD137, a member of the TNF superfamily 
in atherosclerosis and the onset of inflammatory plaques. Its expression in cardiomyocytes, 
vascular endothelial and smooth muscle cells suggest that it promotes atherosclerotic plaque 
development (Olofsson et al., 2008; Tedgui & Mallat, 2006). Its interaction with CD137 ligand 
has been implicated in the activation of the TNF pathway and the development of 
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atherosclerosis (Yan et al., 2013; Olofsson et al., 2008; Tedgui & Mallat, 2006). Recent work 
suggests that CD137-CD137L interaction induces activation of PLC signaling pathway in human 
umbilical vein endothelial cells (HUVEC) (Yan et al., 2013). This PLC signaling pathway 
commonly known for the synthesis of diacylglycerol (DAG) and inositol triphosphate (IP3), plays 
an important role in cellular calcium regulation and sympathetic nerve-mediated smooth 
muscle contraction. In HUVEC, CD137-CD137L interaction produced a concentration-dependent 
increase in DAG and IP3 levels indicating the activation of the PLC signaling pathway by the TNF-
α mediator (Yan et al., 2013). Others have demonstrated the involvement / activation of the 
PLC signaling pathway in other metabolic inflammatory diseases such as diabetes. For example, 
the observation of enhanced insulin release in the pancreas by Suzuki et al. (2011) suggested a 
direct link between interleukin-6 (IL-6) expression and insulin resistance because IL-6 receptors 
were overtly expressed in the murine pancreatic β cells during insulin resistance.  
Therefore, the role of cytokines and their interaction with specific receptors has been 
implicated in the onset and progression of cardiovascular diseases; however, their role in 
adrenoceptor-mediated vascular function (contraction and dilation) has yet to be explored. 
1.4. Vascular smooth muscle cells 
Smooth muscle cells make up the thickest layer of vascular tissue, the tunica media. 
Depending on the vessel, the media could consist of several layers of SMCs ranging from one to 
four or more layers. Within each layer, the smooth muscle cells are arranged in a helical 
fashion, superimposing each other at angles contributing to the ring structure of the vessel 
(Garland & Angus, 2006). For decades, the contractile response of smooth muscle cells has 
SYMPATHETIC NERVE RESPONSE AND VASCULAR FUNCTION                                                                             
33  
been studied in preparations of large arteries using the spiral-cut technique. This spiral-cut 
technique has been used commonly for its advantage that changes in smooth muscle cell length 
were amplified due to the mechanical arrangement of the VSMCs (Garland & Angus, 2006). 
 1.4.1. Electrical properties of VSMCs 
The behavior of vascular smooth muscle cells is controlled by the activity of the 
sympathetic postganglionic nerves (Tank & Lee Wong, 2015). The activation of the sympathetic 
nerves that innervate the smooth muscle cells is dependent on intermittent bursts of varying 
amplitude and frequency (Stjärne, 2000). In particular, this burst discharge and the associated 
excitatory junctional potentials (e.j.p.) are responsible for the arterial smooth muscle cell 
contractions, causing vasoconstriction. On the graded potential principle, single e.j.p.s are not 
enough to produce a threshold potential to activate the sympathetic nerves but a summation 
of single e.j.p.s fire at threshold. At threshold, action potentials cause the sympathetic nerves 
to release their neurotransmitter contents from the varicosities (in distal axons) into the 
“synaptic cleft”. Interestingly, the bursts of e.j.p.s have been associated with the “quantal” 
release of neurotransmitter. Furthermore, within a certain physiological range, there is linear 
relation between vascular contractile response and frequency of stimulation (Bevan, 1978). The 
greater the frequency of firing potentials (pulse), the greater the amount of varicosities that get 
activated and release their noradrenaline (NA) contents in response, and the greater the SMC 
inotropic (contractile) effect. During sympathetic activation, whether NA is released from a 
small percentage of varicosities or small quantities from all the varicosities remains unclear. 
However, the intermittent release of noradrenaline in association with the pulse of activation is 
evident in amperometric studies (Stjärne, 2000). Furthermore, the varying amplitudes and 
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frequencies that produce sympathetic e.j.p.s also seem to have different thresholds in different 
species. In rats for example, low-firing frequencies have been estimated as low as 0.5Hz and 
high-firing as high as 50Hz. Duggan et al. (2011) were able to demonstrate EFS-evoked smooth 
muscle contractile responses in rat pulmonary arteries between 0.6 – 40 Hz. This frequency 
range has been reproducible in the rat femoral artery between 5 – 30Hz (Zacharia et al., 2004). 
1.4.2. Mechanical properties of VSMCs 
 The sympathetic release of noradrenaline and adrenergic receptor activation mediate 
the contractile responses in vascular tissues. Αlpha-adrenoceptor activation (i.e. PLC and 
adenylyl cyclase signaling pathways) induces changes in cytosolic concentrations of calcium 
through the release of calcium from the cell’s internal stores (e.g. sarcoplasmic reticulum). This 
is in contrast to the voltage-dependent influx of calcium from extracellular stores triggered by 
ATP for example. Here, this calcium release (and/or influx) leads to an increase in transient 
intracellular calcium, and activates the myosin-actin contractile machinery (Garland & Angus, 
2006). In the smooth muscle cells, the calcium-bound calmodulin complex activates the myosin 
light chain kinase (MLCK) enzymes to phosphorylate the myosin filaments.  Hence, the active 
calcium-dependent phosphorylated myosin filaments interact with the actin filaments (known 
as the sliding filament mechanism) to form cross-bridges. The cross-bridges cause contraction 
of the myosin-actin complex, and ultimately contraction of the entire smooth muscle tissue. 
The functional significance of the myosin-actin interaction in the vasculature, therefore, is the 
contraction and relaxation of the smooth muscle cells which permits an increase or decrease in 
resistance in vessels, respectively, and regulate blood flow.   
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 Not surprising then, changes in calcium handling proteins can functionally alter the 
smooth muscles ability to contract and relax. In vascular diseases, the expression and function 
of calcium handling proteins (pumps, exchangers and channels) involved in smooth muscle 
contraction and relaxation are often altered (Ewart et al., 2014; Lipskaia et al., 2014).  
1.4.2. Pharmacology of vascular smooth muscle 
In vitro, vascular tissue segments retain much of their neuronal and mechanical 
function, which allows the assessment of the effects of vasoactive agents in isolated target 
tissue (Garland and Angus, 1996). Vasoactive agents such as agonists and antagonists of 
adrenoceptors present the unique opportunity to study the vasomotor properties of smooth 
muscle cells. Phenylephrine is a selective α1-adrenoceptor agonist which produces 
concentration-dependent contractions of vascular smooth muscle cells. The vascular 
concentration-dependent contractile response to PE are abolished by the presence of prazosin, 
a selective α1-adrenoceptor antagonist (Duggan et al., 2011). EFS-contractile response studies 
have demonstrated that the sympathetic contractile response mediated by the NA release is 
also affected by antagonistic action. Selective α1-adrenoceptor antagonists have been shown to 
abolish the sympathetic-mediated responses. Sympathetic-mediated responses are significantly 
decreased (or abolished) by selective α1-adrenoceptor blockers prazosin (Docherty, 2014; 
Duggan et al., 2011, Zacharia et al., 2004), terazosin and doxazosin (Mathur et al., 2014; 
Persson et al., 1998). Similarly, the α-adrenoceptor blocker WB4101 has also been found to 
significantly inhibit field stimulation contractile responses (Duggan et al., 2011). Docherty 
(2014) found greater affinity of prazosin for the α1A- and α1D-adrenoceptors, subtypes 
previously demonstrated to mediate the contractile response in proximal segment of the rat 
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tail artery. Conversely, the selective α2-adrenoceptor blocker rauwolscine has been found to 
have endothelium dependent effects, to either decrease EFS-mediated contractions (Pagan et 
al., 2012) or to augment the nerve-mediated contractile responses (Martinez et al., 2009) in the 
presence of functional endothelium in large arteries. Furthermore, noradrenaline reuptake 
antagonists potentiate the nerve-mediated contractile responses to EFS stimulation. Cocaine, a 
common NA reuptake inhibitor has been to found to enhance the field stimulation frequency-
dependent responses (Docherty, 2014; Duggan et al., 2011). In the presence of cocaine, the 
predominant subtypes (α1A- and α1D-adrenoceptors) involved in VSM nerve-stimulation-evoked 
contractile responses were found to be more sensitive to noradrenaline (Zacharia et al., 2004). 
Altogether, studies have posited differences in the frequency ranges (low, 0.5-5 Hz and high, 
10-40 Hz) where the nerve-mediated contractile responses are most sensitive to the inhibitory 
action of the various antagonists but these frequency-dependent differences remain 
inconclusive.  
1.5. Rationale 
Physiological and pharmacological studies have provided great insight on the function of 
adrenoceptors and increased the understanding of how these receptors function in different 
physiological systems. There is ample evidence that alterations in sympathetic nerve function 
are implicated in a variety of pathophysiological states, and cardiovascular diseases in particular 
(Chistiakov et al., 2015; Derosa et al., 2007; Topal et al., 2006; Tesfamariam et al., 1992; Shafi et 
al., 1989). Furthermore, a body of research has suggested that changes in adrenoceptor 
structure and regulation may also play a role in the development of certain cardiovascular 
diseases (Mathur et al., 2014; Amiya et al., 2014; Pagan et al., 2012). With regards to α-
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adrenoceptors in particular, changes in functionality is related to vascular diseases associated 
with changes in vascular contractile regulation and vascular tone.   
There is now some understanding of how changes in vascular tissue due to 
inflammation may impact the smooth muscle cells and relate to the development of vascular 
diseases such as atherosclerosis and high blood pressure. Nevertheless, it is still unknown how 
the processes that modulate systemic inflammation may affect the adrenoceptors and the 
associated vascular sympathetic function.  Therefore, because drugs targeting these AR’s are 
very important and are widely used in clinical therapy, understanding the changes in 
adrenoceptor structure (/distribution) and function may elucidate understanding to tailor 
clinical therapy for individuals affected by vascular inflammation. The present study aimed to 
investigate the effects of inflammation on vascular alpha-adrenoceptor-mediated contractile 
responses and the neurogenic-mediated vascular function.  
1.6. Hypothesis 
 We believe that chronic inflammation would affect the nerve-mediated contractions of 
blood vessels in rat tail arteries. We have reason to believe that pro-inflammatory cytokines can 
activate smooth muscle cells through activation of the phospholipase C signaling pathway. If 
this occurred, nerve-mediated contractions would be expected to be greater in tail arteries 
from inflamed animals compared to the control rats. Increased vascular tone has been evident 
in inflammatory-mediated vascular diseases as a result of increased sympathetic activity and 
the greater release of the neurotransmitter noradrenaline. Since sympathetic nerve activity 
leads to the activation of adrenergic receptors, the increased outflow of NA would be expected 
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to produce larger α-adrenoceptor-mediated smooth muscle contractions in inflamed animals 
compared to control animals. We expected that NA reuptake blockers would produce a larger 
potentiation of the nerve-mediated vascular contractions in inflamed animals in comparison to 
the controls.  
We also assessed the possibility that a differential distribution (i.e. localization and 
density) of α-adrenoceptors existed in the rat tail artery from inflamed and control animals. In 
addition, functionally, we expected the nerve-mediated contractile responses to activation of 
α1- and α2-adrenoceptors to be altered in inflamed animals compared to the control animals.  
1.7. Objectives 
 The present study aimed to investigate the sympathetic nerve-mediated contractile 
responses resulting from alpha-adrenoceptor activation in blood vessels of animals subjected to 
chronic inflammation in comparison to healthy animals. In order to investigate the above, the 
present study will: 
i. Establish a rat model for chronic systemic inflammation. Compare the levels of TNF-
α (a pro-inflammatory cytokine and marker for inflammation) over time in the 
plasma of treated and control animals using western blots to confirm systemic 
inflammatory response. 
ii. Perform tension-studies to compare vascular nerve-mediated smooth muscle 
contractile responses to EFS.  
iii. Assess the pharmacological characteristics of post-junctional α1- and α2-
adrenoceptors using alpha-adrenoceptor antagonist action on nerve-mediated 
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vasoconstriction to compare adrenoceptor type contributions to SMC contractile 
responses. 
iv. Compare the blocking properties of the adrenoceptor antagonists in the presence or 
absence of the NA uptake blocker, cocaine to assess any differences in NA 
adrenoceptor activation (pathway) in vascular contractile responses in treated vs 
control animals.  
v. Employ immunofluorescence techniques to compare the distribution of alpha 
adrenoceptors and the sympathetic enzyme, tyrosine hydroxylase in the vascular 
tissue segments of treated and normal animals. 
vi. Compare blood pressure changes over time, to verify normal blood pressure in the 
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2.0. Materials and methods 
 2.1. Animals 
All procedures on animals were performed in accordance with the guidelines and 
regulations of the Canadian Council on Animal Care, with the approval of the Institutional 
Animal Care Committee of Memorial University of Newfoundland. Male Sprague Dawley rats 
(5-6 weeks, 200-300 g) were housed in plastic cages in a temperature-controlled environment 
(22+/- 2 OC) on a 12:12h light/dark cycle. Animals were allowed access to regular chow and tap 
water, ad libitum. 
2.2. Fine chemicals  
 Isofluorane was purchased from Halocarbons Products Corporation (USA). 
Buprenorphine was purchased from Schering Plough Ltd (UK). Heparin sodium was obtained 
from SoloPak Laboratories Inc. (USA) and Sigma-Aldrich Inc. (USA). Cocaine and tetrodotoxin 
were supplied by Sigma-Aldrich Inc. (USA). Research Biochemical International (USA) supplied 
rauwolscine hydrochloride, prazosin hydrochloride, WB4101, phenylephrine hydrochloride and 
methylcholine hydrochloride. Ketamine hydrochloride was supplied by Bimeda-MTC Inc. 
Xylazine hydrochloride was supplied by Bayer Health Care Inc. α1 and α2b-adrenergic receptor 
antibodies were purchased from Abcam Inc. (Toronto, ON). Anhydrous ethyl alcohol was 
obtained from Commercial Alcohols and hydrochloric acid was obtained from Fischer Scientific.  
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2.3. Animal model: chronic (systemic) inflammation 
 Systemic inflammation was established similar to the methods used by Schopf et 
al. (2006) by intradermal injection of Complete Freund’s adjuvant (CFA; heat killed 
Mycobacterium butyricum suspended in mineral oil). Animals were anaesthetized with 
isofluorane (induced at 5% in 100% oxygen; maintained at 1.5-2.0% in 100% oxygen) delivered 
using masks. Left paws were surgically prepped (1: Betadine; 2: 70% Alcohol; 3: Chlorhexidine). 
CFA (0.05 - 0.07 ml) was injected intradermally in the hind left footpad of treatment animals. 
Sham-operated animals received equivalent volumes of saline. Flumazine was applied topically 
at the injection sites after injection to prevent infection.  
Animals were then returned to cages and maintained on heat pads during recovery until 
they regained consciousness (physical activity). Buprenorphine (0.03 mg/kg; 0.5 mg/mL in 
normal saline) was administered subcutaneously immediately following surgery and at q12hr in 
CFA-treated animals for three weeks.  
2.4. Measurement of parameters 
Blood Pressure. 
Blood pressure (BP) of animals was measured weekly (for three weeks) using the non-
invasive tail cuff method (plethysmography, IITC Life Science warming chambers) in wake 
animals from Day 0 (prior to inflammation). Before BP recording, animals were allowed to 
acclimatize in a warming chamber equipped with fans (IITC Life Science Warming Chambers; 
internal temperature set at 300C) for half an hour. Systolic BP readings were recorded with a 
Bonwin computer software.  
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 Plasma samples 
Blood samples were collected weekly for three weeks, starting on Day 0 before 
injection. Animals were anaesthetized with isofluorane (induction: 5% isoflurane, 100% oxygen; 
maintenance: 2.5% isofluorane, 100% oxygen) and placed on a heating pad. Blood (0.5-0.7 ml) 
was collected from the left or right tail veins using heparin-coated syringes. Blood samples were 
then centrifuged at 15,000 x g rpm (Legend Micro 21, Thermo Scientific) for 15 minutes at 40C. 
Plasma was separated, transferred to labeled tubes and stored at -800C for analysis of systemic 
inflammation. 
 Body weight and paw assessment. 
Body weight, ankle and paw volume were measured in 1-2 day intervals, starting on Day 
0 for three weeks. Animals were weighed using a regular digital weight scale. Ankle and paw 
measurements (left and right) were obtained using digital calipers to assess the inflammatory 
response. Inflammation was also assessed with a water displacement method of the ankle and 
paw (left and right). The weight of the displaced volume of water indicated the volume of the 
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2.5. Experimental preparation for Force-tension studies 
 2.5.1. Buffer solution 
Krebs buffer was prepared from a mixture of two solutions of the following composition 
(mM) similar to Duggan et al. (2011): 130 NaCl, 4 KCl, 1.2 MgCl2.6H2O, 2.5 CaCl2.2H2O, 12.5 
NaHCO3, 1.2 KH2PO4 and 0.1 EDTA. A solution of high potassium (80mM) was also prepared 
where equimolar levels of sodium were replaced with potassium. Media solutions were gassed 
with 95% O2 and 5% CO2 at all times and maintained at 370C in a water bath. 
2.5.2. Animals 
Following the three week monitoring period, animals were sacrificed. Rats were 
anaesthetized with a mixture of 20 mg/ml Rompun and 50 mg/ml Ketalean (1:1 ratio) by 
intraperitoneal injection (i.p.). To induce full anesthesia, the dosage was adjusted while 
monitoring animal reflexes by toe-pinching. A midline incision from the xiphoid process to the 
neck provided access to the thoracic cavity. Animals were exsanguinated from the left ventricle, 
and the ventral caudal arteries were quickly extracted and placed in Krebs buffer.  
 2.5.3. Ventral tail artery 
The proximal end of the ventral tail arteries was isolated. Helical strips (segments 
approximately 1.5 – 2 cm) were dissected in Krebs buffer gassed with 95% oxygen and 5% 
carbon dioxide at all times (pH: 7.4). Helical strips were then mounted on holders with rings of 
platinum electrodes, connected to an electric field stimulation system (Grass S88 stimulator). 
Tissues were placed in organ baths containing 20 ml Krebs buffer (gassed with 95% O2 and 5% 
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CO2, maintained at 370C and 7.4 pH) and connected to a force displacement transducer. 
Vascular contractile responses were recorded on a PC-based data acquisition system, 
AcqKnowledge 3.9.1 (Biopac Systems Canada Inc.). 
2.6. Experimental protocols for Force-tension studies 
 Tissues were subjected to a resting preload tension of 200 mg (pre-determined by 
concentration-dependent force-tension curves to phenylephrine) and allowed to equilibrate in 
baths for 30 minutes. Contractile responses of tissues to electric-field stimulation were then 
studied. Effects of pharmacological agents to field-stimulated contractions at various 
frequencies were investigated. Tissues were washed three times with Krebs buffer every half 
hour and allowed to stabilize initially for 40-45 minutes.  
Samples of the caudal artery (approximately 5-10 mm, buffered at pH 7.4) from animals 
were also fixed in 10% formalin and embedded in paraffin blocks for immunohistochemical 
studies. Sections were cut at 4-5 microns, placed on slides as needed and preserved at 40C for 
staining.   
2.6.1. Electric Field Stimulation 
 Sympathetic nerves were stimulated with electric field stimulations similar to the 
method of Duggan et al. (2011). Frequency-dependent contractile responses were performed 
by exposing isolated tissues to electric fields of varying frequencies. A Grass Stimulator 
delivered electricity (100 mA, 50 V, 0.5 ms) through the platinum electrode rings on the tissue 
holders.  
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 Tissues were stimulated at 50 V with a 0.5 ms pulse duration at varying frequencies 
(1.25-40 Hz). After equilibration, the tissues were subjected to three blocks of stimulation in the 
presence or absence of a pharmacological agent and/or vehicle. A total of nine pharmacological 
groups were tested (See Table I in appendix). Tissues were washed with Krebs solution after 
each stimulation block and allowed to equilibrate for 20-30 minutes. 
 Tissues were assigned to pharmacological groups on an ad hoc basis. The presence of 
functional endothelium was randomly assessed in tissues with methacholine (10-6 M) after a 
contractile response to phenylephrine (10-6 M). Furthermore, the neurogenic origin of the 
contractile responses was verified with field stimulations by addition of tetrodotoxin (TTX, 10-7 
M) to the bath. Maximal contractile responses were produced in all tissues after field 
stimulated contractions with a solution of high potassium (80 mM) for normalizing of 
responses.   
 2.7. Assessment of systemic inflammation   
  TNF-α determination 
Blood samples (collected weekly) of five randomly selected animals per group were 
analyzed for tumor necrosis factor-alpha (TNF-α) using the enzyme-linked immunosorbent 
assay (ELISA) technique. The ELISA protocol was provided with the Rat TNF-α ELISA Deluxe kit 
(Biolegend, San Diego. Ca). Immunohistochemical (IHC) techniques were also used to assess the 
expression of ionized calcium adapter binding molecule-1 (Iba-1) in paraffin-preserved vascular 
tissues. IBA-1 is specifically expressed in macrophages and microglial cells and is particularly 
upregulated when macrophages are activated systematically. 
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 ELISA assessment of TNF-α in flash frozen plasma samples was performed as directed by 
the manufacturer (Biolegend, San Diego, CA, USA). Plate wells were coated with 100ul of mixed 
capture buffer solution (capture antibody in coating buffer) and incubated overnight at 40C. 
Plasma samples were thawed overnight at -200C from -800C. On the following day, plates were 
washed (four times) with wash buffer (0.05% tween20 in PBS). After wash, plates were blocked 
with 200µl 1X assay diluent in Phosphate-Buffered Saline (PBS; 8.0 g NaCl, 1.16 g Na2HPO4, 0.2 g 
KH2PO4, 0.2 g KCl in distilled water to 1000 ml) for one hour at room temperature on a shaker 
with circular orbit. Plates were washed again (four times) with wash buffer. Standard solutions 
were prepared as follows: 100ul of reconstituted standard (1:100 dilution of stock in 1X assay 
diluent). Six, two-fold serial dilutions of the top standard were performed. 1X assay diluent 
served as a zero standard. 50µl of Matrix A was loaded unto standard dilution wells; whereas 
50µl of 1X assay diluent was loaded unto sample wells. Thereafter, 50µl of standard dilutions 
and plasma samples were added to the appropriate wells and incubated on shaker at room 
temperature for 2 hours. Plates were again washed (four times) with wash buffer. 100µl of 
diluted detection antibody (1:200 in assay diluent) was added to wells and incubated on shaker 
at room temperature for one hour. Plates were again washed (four times) with wash buffer. 
Thereafter, 100µl of Avidin-HRP diluted solution (1:1000 in assay diluent) was loaded into wells 
and incubated on shaker at room temperature for 30 minutes. Plates were washed (five times) 
allowing 1 minute per wash.  Wells were then incubated in the dark with 100µl of freshly mixed 
TMB substrate (5.5 ml Solution A and 5.5 ml Solution B) for 25 minutes. 100ul stop solution was 
quickly added to the wells and plates read within 15 minutes at 450-570nm absorbance.  
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2.8. Immunofluorescent staining 
α1 & α2b- adrenoceptors 
Immunofluorescence (IF) was used to assess the expression and localization of alpha 
adrenoceptors and the sympathetic nerve neurotransmitter enzyme tyrosine hydroxylase (TH 
co-localized with α-2b adrenoceptor) in the smooth muscle and endothelium of rat tail artery. IF 
staining was performed similar to the methods of Daneshtalab et al. (2010). Slides were 
deparaffinized in xylene (x2) and rehydrated in series dilutions of ethanol. Afterwards, 
endogenous peroxidase was blocked by incubating in 3% hydrogen peroxide for 15 minutes. 
Samples were then blocked with 10% horse serum and 0.1% triton x in phosphate-buffered 
saline (PBS) for 30 minutes in a humid chamber. Antigen retrieval was achieved by exposing 
samples to 1% Sodium Dodecyl Sulphate (SDS) at room temperature for 5 minutes. Sections 
were washed in PBS on a tilt tray after every step for 3 minutes. After antigenic exposure, 
samples were incubated overnight at 40C with either a primary rabbit polyclonal alpha-1 (1:75 
in 2% horse serum; Abcam, Toronto, ON.) or mouse monoclonal alpha-2b antibody (1:75 in 2% 
horse serum; Thermoscientific, Burlington, ON) and rabbit tyrosine hydroxylase antibody (1:750 
in 2% horse serum; Abcam, Toronto, ON). 2% horse serum (HS) was prepared in PBS.  
The following day, the sections were washed sequentially with Tris-Buffered saline with 
Tween20 solution (TBST; 20mM Tris Base, 150mM NaCl and 50mM tween20) for 10 minutes. 
After primary antibody removal, the respective secondary antibody was added: 1:300 against 
cy2 goat anti-rabbit, 1:300 against cy2 goat anti-mouse and 1:250 against cy5 goat anti-rabbit in 
2% HS for 30 minutes respectively at room temperature. Secondary antibody incubation and 
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washes were completed in an aluminum-covered humid chamber and tilt trays to limit access 
of light (in dark). Afterwards, secondary antibodies were washed four times with TBST for 10 
minutes. Sections were flooded with 50% glycerol and covered with coverslips tight and bubble-
free. Edges were sealed with transparent nail polish to hold coverslips in place.  
IBA-1 staining 
A similar IF staining protocol was used for IBA-1 staining, in the vascular tissues. After 
deparaffination, sections were hydrated through graded alcohols to water. Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxide for 15 minutes in a humid chamber 
and rinsed with 1X PBS. Antigen retrieval was achieved by incubating sections in a lid-covered 
dish containing citrate buffer placed in a steamer (at 95-1000C) for 30 minutes. Afterward, the 
dish was removed from the steamer and allowed to cool at room temperature for 
approximately 20 minutes. Vessels were rinsed with PBST (3% triton x in 1X PBS). Sections were 
blocked with 10% normal goat serum (NGS, in Tris-Buffered saline) in a humid chamber at room 
temperature for 2 hours. Sections were again rinsed with PBST. After blocking, sections were 
incubated overnight at 40C with primary rabbit polyclonal Iba-1 antibody (Abcam, Toronto, ON. 
CA) prepared as 1:1000 dilution in 2% NGS.  
The following day, sections were rinsed (twice) and washed (four times) in 1X PBS on a 
tilt shaker at room temperature. Then, sections were incubated with secondary antibodies 
against rabbit Iba-1: cy2 goat anti-rabbit (1:200 in 2% NGS) and 4’ 6-diamidino-2-phenylindole 
(DAPI; 1:1000 in 2% NGS) for 30 minutes in the dark (aluminum-covered humidifier). Afterward, 
sections were rinsed (twice) and washed (four times) with 1X PBS at room temperature on a tilt 
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shaker for 10 minutes. Sections were drained and dried with absorbent paper (kimwipes) and 
flooded with 50% glycerol (glycerol in 1X PBS). Section slides were covered with coverslips and 
sealed with transparent nail polish.  
Slides were imaged at 20X magnification using confocal microscopy and analyzed with 
Fluoview software (Olympus Fluoview, FV100). Sections from five slides of different animals per 
group were stained and imaged. The same laser parameters (laser intensity, transmitted light 
and offset) were used to image all sections for each IHC staining group (1. Alpha-1 and 2. Co-
localization of alpha-2b and tyrosine hydroxylase).  
2.9. Analysis  
2.9.1. Data measurements and calculations 
 Mean systolic BP, weight, ankle and paw volumes were calculated as an average of 
three data points. EFS contractile response curves were analyzed for area under the 
mechanogram. Areas under the response curve were calculated as a total area sweep under the 
curve from baselinei to baselinef. All data points were normalized as a percentage of the area 
(30 seconds after rise) to the high potassium-induced maximum contractions. 
2.9.2. Statistical analysis 
All measurements (area under the mechanogram) for the electric field-evoked 
contractions were calculated as a percentage of the contractile response to the high potassium 
solution of the respective tissue to normalize the data. Analysis were completed with SigmaPlot 
12.0 (SPSS Inc., USA). Unpaired t-test of samples was carried out for the contractile responses 
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(control) in the absence of test drugs or vehicle (area under the mechanogram) between the 
CFA and Saline groups. Two-way analysis of variance (ANOVA) were carried out for comparisons 
of pharmacological effect within and between CFA and Saline groups, across frequency 
stimulations. The data are based on replications from at least 7 individual animals. Unpaired t-
test was also carried out for animal systolic BP, weight, and ankle and paw size. 
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3.0. Results 
 CFA and saline groups of rats had similar mean blood pressures prior to treatment. 
There were no significant differences in the mean systolic blood pressure of saline-treated and 
CFA-treated rats over the period of 4 weeks (Table 1). 
 Baseline weights were not significantly different between saline and CFA groups. 
Animals treated with CFA had a significantly lower weight compared to their saline 
counterparts, over time (Figure 4). 
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Table 1. Mean systolic blood pressure of rats treated with saline or CFA over time. Mean + 
standard error of mean. P>0.05 in all comparisons. N = 25 (in each condition) 
 Week 1 (baseline) Week 2 Week 3 Week 4 
Saline-treated 
(mmHg) 
167.7 + 4.8 162.7 + 6.0 159.4 + 3.9 157.2 + 4.8 
CFA-treated 
(mmHg) 
166.5 + 5.4 166.4 + 6.2 163.6 + 4.9 158.5 + 3.7 
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Time (Days)
























Figure 4. Body weight of animals treated with saline or CFA over time. Mean + standard error of 
mean.  
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3.1. Assessment of chronic inflammation 
 
Plasma TNF-alpha 
Plasma levels of TNF-α at baseline were not significantly different between CFA- and 
saline-treated animals. However, the levels of TNF-α in CFA-treated rats became significantly 
elevated compared to their saline counterparts after 14 days (Figure 5). There was no 
significant increase in the levels of plasma TNF-α of saline-treated animals.  
Paw measurements  
Baseline mean ankle and paw volume (left and right) were not significantly different 
between CFA- and saline-treated animals. The mean displacement volume of the left paws 
(injection site) of CFA rats became significantly larger compared to the left paw of saline rats at 
respective measurement points (Figure 6A). Mean displacement volume of contralateral paws 
became significantly different 14 days after treatment (Figure 6B).  
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700 CFA (n = 5) saline (n = 5) 
 
Figure 5. Levels of TNF-α in plasma of inflamed (CFA) and non-inflamed (SAL) animals. Mean + 
standard error of mean. 
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Figure 6. Mean volume of left (A) and right (B) paws of CFA- and saline-treated animals using 
water displacement method. Mean + standard error of mean.  
a significantly different compared to paws of saline-treated rats. p<0.05. 
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3.2. Electric field stimulation responses in rat tail artery 
Electrical field stimulation elicited contractions in helical strips of rat tail arteries at 50 V 
and 0.5 ms pulse width. Progressive increase in frequency of stimulation (1.25 – 40 Hz) resulted 
in greater contractions. However, EFS-evoked contractions were completely abolished at all 
frequencies in the presence of tetrodotoxin (TTX; 10-7 M), and hence were considered 
neurogenic in origin. 
3.3. Effect of inflammation on EFS-evoked contractions 
 Electrical frequency stimulations produced significantly greater contractile responses in 
CFA- compared to saline-treated group of rats at respective frequencies. This difference in 
response was noted at the low and high frequencies ranging from 2.5 to 40 Hz (Figure 7). 
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saline-treated (n = 27) CFA-treated (n = 28)
 
Figure 7. Electric field-evoked contractions in CFA- and saline-treatment groups of rats at 
frequencies indicated. Mean + standard error of mean. Contractions were elicited at 50 V and 
0.5 ms pulse width for 30 seconds. 
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3.3.1. Effect of Prazosin and WB4101 on EFS-evoked contractions 
The presence of the selective α1 antagonist prazosin (0.3 μM) produced significant 
reductions in EFS-elicited contractions at higher frequencies of stimulation (10 – 40 Hz) in tail 
arteries of CFA- and saline-treated rats compared to the respective control responses (Figure 
8A & B). In blood vessels of CFA rats, however, prazosin significantly attenuated field stimulated 
contractions in the frequency range of 1.25 – 5 Hz compared to responses in saline-treated 
animals (Figure 8B). 
Similarly, WB4101 (0.03 μM) significantly attenuated the EFS-evoked contractions in tail 
arteries of CFA- and saline-treated groups of rats at higher frequencies of stimulation (10 – 
40Hz) compared to the corresponding control responses (Figure 9A & B). In blood vessels of 
CFA rats, however, WB4101 significantly reduced electric field-evoked contractions at lower 
frequencies of stimulation between 1.25 and 5 Hz, compared to the field-stimulated responses 
in blood vessels of saline-treated rats. There was no significant difference in the effect of 
WB4101 on EFS-evoked contractions between CFA- and saline treatment groups. 
The pattern of inhibition indicated a greater contribution of α1-adrenoceptors mediated 
contractions in the blood vessels from CFA-treated animals compared to saline-treated animals 
(Figure 8A & B; 9A & B).  
3.3.2. Effect of rauwolscine on EFS-evoked contractions 
There was no significant difference in EFS-evoked contractions in the presence of 
rauwolscine between CFA- and saline-treated groups of rats, compared to the control 
responses at respective frequencies of stimulations (Figure 10A & B).  
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80 CFA - control (n = 7) 




Figure 8. The effect of prazosin on EFS-evoked contractions in tail artery of saline- (A) and CFA- 
treated (B) rats. Mean + standard error of mean. Pra, Prazosin. Contractions elicited at 50 V and 
0.5 ms pulse width for 30 seconds. 
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80 saline - control (n = 7)
saline - WB4101 (0.03 M) (n = 7) 
A
Frequency (Hz)














80 CFA - control (n = 7) 
CFA - WB4101 (0.03 M) (n = 7) 
B
 
Fig 9. Effect of WB4101 on EFS-evoked contractions in tail arteries of saline- (A) and CFA-
treated (B) rats at frequencies indicated. Mean + standard error of mean. Contractions elicited 
at 50 V and 0.5 ms width for 30 seconds. 
a significantly different compared to control responses at respective frequencies. p<0.05. 
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80 saline - control (n = 7)
saline - rauwolscine (3.0 M) (n = 7) 
A
Frequency (Hz)














80 CFA - control (n = 7) 
CFA - rauwolscine (3.0 M) (n = 7) 
B
 
Figure 10. The effect of rauwolscine on the EFS-evoked contractions in saline (A) and CFA (B) 
treatment groups at frequencies indicated. Mean + standard error of mean. Contractions 
elicited at 50 V pulse train and 0.5 ms pulse width for 30s. Rau, Rauwolscine. p<0.05. 
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3.3.3. Effect of cocaine on EFS-evoked contractions 
Cocaine significantly enhanced EFS-evoked contractions in tail arteries of CFA- and 
saline treated animals at frequencies of stimulation between 5 and 40 Hz, compared to the 
corresponding controls (Figure 11 & 12). There was no significant difference in the effect of 
cocaine on the EFS-evoked contractions in blood vessels from CFA- and saline-treated group of 
animals.  
Effect of rauwolscine in the presence of cocaine  
Rauwolscine (3 μM) had no effect on EFS-evoked contractions in the tail arteries of CFA- 
and saline-treated rats in the presence of cocaine (1 μM). There was no significant effect of 
rauwolscine on cocaine-enhanced contractions from blood vessels of CFA and saline-treated 
groups of animals (Figure 11A & B). 
Effect of WB4101 in the presence of cocaine 
WB4101 (0.03 μM) significantly attenuated the EFS-evoked contractions in the presence 
of cocaine (1 μM) compared with the corresponding controls in tail arteries of CFA and saline-
treated group of animals between 5 and 40 Hz (Figure 12A & B). In blood vessels of CFA rats, 
WB4101 also significantly inhibited contractions in the presence of cocaine at the lower 
frequencies of stimulation (1.25 – 2.5 Hz) (Figure 12B). There was no significant effect of 
WB4101 in the presence and absence of cocaine between CFA and saline group of animals. 
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100 CFA - control (n = 7)
CFA - cocaine (1.0 M) (n = 7) 
CFA - cocaine (1.0 M) + Rauwolscine (3.0 M) (n = 7)
B
 
Figure 11. Effect of cocaine in the absence and presence of rauwolscine on electric field-evoked 
contractions in tail arteries of saline (A) and CFA (B) rats. Contractions elicited at 50 V and 0.5 
ms pulse width for 30 seconds. Mean + standard error of mean. Co, Cocaine; Rau, Rauwolscine. 
a significantly different from control at respective frequencies. p<0.05. 
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saline - cocaine (1.0 M) + WB4101 (0.03 M) (n = 6) 
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100 CFA - control (n = 6)
CFA - cocaine (1.0 M) (n = 6) 
CFA - cocaine (1.0 M) + WB4101 (0.03 M) (n = 6)
B
 
Figure 12.  Effect of cocaine on the EFS-evoked contractions in tail arteries of saline (A) and CFA 
(B) treated animals in the absence and presence of WB4101. Contractions elicited at 50 V and 
0.5 ms pulse width for 30 seconds. Mean + standard error of mean. Co, Cocaine; WB, WB4101. 
a significantly difference from control at respective frequencies.  
b significantly different from cocaine-enhanced contractions. p<0.05. 
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3.3.4. Effect of vehicle on EFS-evoked contractions 
 Water (dH2O) had no effect on the contractile responses to EFS in blood vessels of both 
saline and CFA treated rats (Figure 13A & B). Contractile responses were comparable in the 
cumulative stimulations over time at corresponding frequencies. 
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80 CFA - control (n = 8) 
CFA - 20 l H2O (n = 8)
CFA - 60 l H2O (n = 8)
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Figure 13. Effect of vehicle on electric field-evoked contractions in tail arteries of saline (a) and 
CFA (b) treated animals at frequencies indicated. Contractions were elicited at 50 V and 0.5 ms 
pulse width for 30 seconds. Mean + standard error of mean.  
 




Localization of α1- and α2b- adrenoceptors as well as tyrosine hydroxylase were 
characterized using immunofluorescent techniques.  Immunofluorescence revealed expression 
of α1-adrenoceptors on the endothelial cells of blood vessels from CFA-treated but not saline-
treated animals. There was similar expression of α1-adrenoceptors on the smooth muscle cells 
of vascular tissues from CFA versus saline-treated animals (Figure 14).  
 The presence of α2b-adrenoceptors was more abundant in endothelial cells of blood 
vessels from saline compared to CFA-treated rats (Figure 15). There was no difference in the 
enzymatic expression of tyrosine hydroxylase in the vascular tissues from CFA-treated animals 
compared to saline-treated animals (Figure 16). 
 Finally, immunofluorescence revealed significant difference in the expression of IBA-1 
(DAPI stain) in the adventitia of blood vessels from CFA-treated animals compared to blood 
vessels from non-inflamed animals (Figure 17). These data suggest massive infiltration of the 
sympathetic nerve plexus with macrophages in the adventitia. 
  




Figure 14. Qualitative expression of alpha1-adrenoceptors in tail arteries of CFA-treated (A) and 








Figure 15. IHC expression of alpha2b in blood vessels of CFA-treated (A) and control (B) animals. 
A 
B 




Figure 16. Immunofluorescent expression of tyrosine hydroxylase in blood vessels of CFA-








Figure 17. Examples of DAPI stain of IBA-1 expression in blood vessels from CFA-treated (A) and 
control (B) animals. 
B 
A 
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4.0. Discussion  
In the present study, the effect of chronic inflammation on field stimulation evoked 
contractions in rat tail arteries was investigated. Induction of inflammation resulted in 
significant elevation in the levels of plasma TNF-α in CFA-treated animals compared to the 
saline-treated animals. Electrical field stimulation-evoked contractions in arteries of CFA 
animals were significantly greater than in saline animals. The selective sodium channel blocker, 
tetrodotoxin abolished the field stimulation-evoked contraction, confirming their neurogenic 
nature. 
Contractions elicited at lower frequencies were significantly attenuated by alpha1-
adrenergic antagonism in arteries of CFA-treated rats compared to saline-treated animals. IHC 
expression of alpha1-adrenergic receptor observed in the endothelium of blood vessels of 
inflammed rats differed from α1 expression in blood vessels of control animals. Similarly, IHC 
revealed differential expression of alpha2b-receptors in the endothelium of blood vessels of 
CFA-treated versus control rats. The effect of the neuronal uptake inhibitor cocaine, in 
enhancing electrical evoked contractions were comparable in blood vessels of CFA-treated and 
saline-treated animals. Furthermore, evidence seem to indicate the neurogenic response 
mediated by α2-adrenoceptors did not play a significant role in the process of contraction, since 
neurogenic contractions were also not affected by alpha2-receptor antagonism in inflammed 
and non-inflammed animals. 
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4.1. Tumor Necrosis Factor - alpha 
Inflammation is a normal biological response to foreign particles. However, continuous 
exposure to a foreign stimulus causes chronic inflammation (Warrington et al., 2011). Sprague-
Dawley rats represent an excellent model for chronic inflammation in vivo (Schopf et al., 2006). 
Serum levels of cytokines TNF-α and IL-6 have been reported to be consistently elevated after 
CFA injection with peak plasma levels between days 12 and 19 (Schopf et al., 2002). 
In this model of adjuvant-induced arthritis, previous investigations have found an 
elevation in the levels of cytokines in systemic circulation as well as increased mean volume of 
the injected and counter-lateral paws of animals (Weichman, 1989). Similarly, Smith-Oliver et 
al. (1993) have also detected elevated levels of TNF-α and IL-6 in serum of adjuvant arthritic 
rats. In line with these findings, Phillipe et al. (1997) also noted a spike in serum TNF-α and IL-6 
12 hours after CFA injection in adjuvant arthritis rats. In addition, it has also been reported that 
significant increases in plasma TNF-α levels in adjuvant-induced arthritic rats occur between 11 
and 25 days after CFA injection (Szekanecz et al., 2000). 
In present study, CFA caused inflammation with a significant increase in plasma levels of 
TNF-α and mean paw volume in left and right hind paws of CFA-treated rats over time. These 
findings are in accord with previous evidence in the literature, and that seem to have a systemic 
component (Schopf et al., 2006). The systemic manifestation of the response is evident by the 
elevated levels of cytokines in peripheral circulation and swelling of the contralateral paws. 
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4.2. Effects of inflammation on sympathetic nerve response in tail artery 
Alpha-adrenoceptor activation mediates the effects of sympathetic nerve stimulation in 
vascular tissue. The rat tail artery is densely innervated with sympathetic nerves that release 
noradrenaline. Electrical field stimulation of sympathetic nerves causes the release of 
neurotransmitter from neurons which then activates α-adrenoceptors leading to 
vasoconstriction (Stjärne, 2000). In the current study, neurogenic contraction as calculated by 
the area under curve was greater in blood vessels from inflamed rats compared to non-
inflamed rats. Based on this observation, it is possible that the neuroeffector pathways leading 
to vascular smooth muscle function in chronic inflammation may have been altered.  
A viable explanation could be that the elevated expression of plasma TNF-α may have 
contributed to the enhanced activation of adrenergic receptors mediated by sympathetic 
neurotransmission. Thus, the pro-inflammatory effect on sympathetic nerves could have 
contributed to (i) the increased release of the transmitter noradrenaline from sympathetic 
nerve endings, or (ii) enhanced response at the receptor level, or both. There is evidence that 
elevated levels of TNF-α in acute septic conditions upregulate sympathetic nerve activity at the 
neuronal level (Xie et al., 1993) through increased intracellular Ca2+ signaling (Shu et al., 2007; 
Dellinger et al., 2008; Lukewich et al., 2014). On this premise, one could postulate that an 
increased release of noradrenaline, hence increased adrenergic receptor activation, leads to 
the observed increase in vascular smooth muscle contraction. However, the effect of the 
neuronal uptake inhibitor, cocaine, in our current data does not support this possibility, 
suggesting perhaps an alternative explanation. All the same, more studies are needed to 
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investigate further the role of inflammatory cytokines (in chronic inflammation) on the 
neurogenic release of noradrenaline.  
It is also possible that TNF-α may have affected adrenoceptor activation by altering the 
signaling pathway processes responsible for vascular contraction. On this premise, alterations 
in the phospholipase C signaling pathways could have led to changes in the contractile response 
in blood vessels of inflamed rats. In addition, because vasoconstrictor-stimulated Inositol 1,4,5-
triphosphate (IP3) formation is also dependent on extracellular Ca2+ (Brock et al., 1989; 
Morimoto et al., 1990, Dickenson et al., 1993), the indirect activation of PLC in smooth muscle 
by circulating TNF-α could have contributed in some way to the current observation (Garland 
and Angus, 1996). Comparatively, there is evidence that the inflammatory response is 
modulated by a cross-talk between the immune system and the central nervous system. This 
dual regulation could involve hormonal and neuronal mechanisms through the hypothalamic-
pituitary-adrenal (HPA) axis and may impact the release of noradrenaline from the sympathetic 
nerves. Here, the sympathetic nervous system provides feedback to organs regulating the 
inflammatory response through the secretion of catecholamines from postganglionic 
sympathetic neurons (Lukewich et al., 2014). In turn, the immune system may also affect the 
CNS through the release of cytokines (Eskandari et al., 2003). In addition, TNF-α and IL-6 have 
been found to induce changes in vascular physiology in vivo (Tracey and Cerami, 1994; Holden 
and Pakula, 1996). Sternberg (1997) has shown that TNF-α can stimulate neuroendocrine 
responses in the CNS of animals in vivo through activation of the hypothalamic-pituitary-
adrenal (HPA) axis. On the basis of this regulatory interplay, further investigation might provide 
insight into the effects of cytokines and chronic inflammation on the sympathetic nerve-
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mediated vascular contractions, in vivo. Therefore, the elevation of plasma TNF-α levels and 
other cytokines during the inflammatory process may have caused permanent change in the 
alpha adrenoceptor-mediated effects. This may have resulted in the modest, but significant, 
enhancement of neurogenic contraction observed in the tail artery of inflamed animals. 
Alpha-adrenoceptor blockers invariably inhibit the effects of sympathetic nerve-released 
noradrenaline by competitively blocking the activation sites of post-junctional receptors. 
Ligand-binding studies have characterized alpha-adrenoceptor subtypes by their effect on 
sympathetic nerve activation. Zacharia et al. (2004) have demonstrated that α1-adrenergic 
receptors play a predominant role in blood vessel contractile responses to sympathetic nerve 
activation compared to α2-adrenergic receptors. Kimikihara et al. (2007) have also 
demonstrated that specific α1-subtypes play a role in smooth muscle contractions in proximal 
segments of rat tail arteries. Furthermore, as demonstrated by Zacharia et al. (2013), α1A- and 
α1D-adrenoceptor subtypes contribute to over fifty percent of contractile response to 
sympathetic activation in vascular tissues. The selective α1 antagonist prazosin has been shown 
to exhibit selective antagonism to α1-adrenoceptor activation (Bao and Stjärne, 1993; Zacharia 
et al., 2004; Zacharia et al., 2013). In addition, the α-adrenoceptor antagonist WB4101 is known 
to significantly inhibit nerve-mediated contractions in vascular smooth muscles, whereas the 
selective α2 blocker rauwolscine has been found to only modestly inhibit the neurogenic 
contractions in vascular tissues of rats and pigs (Bao and Stjärne, 1993; Duggan et al., 2011).  
In the present study, prazosin and WB4101 had a variable effect on field stimulation-
evoked contractions in tail arteries of CFA-treated rats compared to saline-treated rats. 
Prazosin had a significant effect on vasoconstriction at higher frequencies of stimulation in both 
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inflamed and non-inflamed rats, but the antagonism was also evident at lower frequencies of 
stimulation in inflamed animals. Possible explanations for this effect are (i) an alteration in the 
sensitivity of the adrenoceptors and/or receptor affinity for the selective ligands or (ii) an 
alteration in the post-receptor mediated events, i.e., the signaling processes leading to 
excitation-contraction coupling. Prazosin has been found to inhibit contractions due to 
electrical-field stimulation in rat femoral and pulmonary arteries in the frequency range of 5 – 
30 Hz (Zacharia et al. 2004; Duggan et al., 2011). However, the effective blocking at the lower 
frequencies (1.25 – 2.5 Hz) in vascular smooth muscle of CFA-treated rats could also suggest 
that α1-adrenoceptor in tail arteries from CFA rats were more sensitive to α1 blockade relative 
to controls. Furthermore, characterization of transmission from peripheral sympathetic nerves 
to vascular smooth muscles has demonstrated that the largest smooth muscle responses occur 
in the low frequency range between 0.2 – 0.5 Hz in conscious rats (Stauss and Kregel, 1996; 
Stauss et al., 1997). This physiological frequency range of stimulation is also believed to be the 
most important in the sympathetic modulation of vasomotor activity in rats and humans 
(Milliani et al., 1991; Stauss et al., 1998). In addition, Luckensmeyer and Keast (1998) 
demonstrated a similar finding in smooth, intestinal muscles in a 0.5-5 Hz frequency range of 
stimulation. These observations emphasize the physiological relevance of alterations in α1-
adrenoceptor activation as noted here in the low frequency range of CFA-treated rats. 
Conversely, this study also found no effect of α2 blockade on the neurogenic 
contractions in blood vessels of inflamed and non-inflamed animals. This corroborates previous 
findings that α2-adrenoceptors play only a modest role in mediating vascular smooth muscle 
contractions (Bao et al., 1993; Bao and Stjärne, 1993; Zacharia et al., 2004). Furthermore, there 
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was no effect of inflammation in the physiological response to α2-adrenoceptor activation, 
suggesting that the difference in EFS-evoked contractions in blood vessels from inflamed and 
non-inflamed rats were unlikely due to alteration in α2-adrenoceptor-mediated responses. 
Nevertheless, there is evidence that inflammation impacts the negative feedback functioning of 
pre-synaptic α2A-adrenoceptors in vivo, leading to increased release of noradrenaline (Hoch et 
al., 2015). It is still unclear, however, whether the α2-adrenoceptors involved were adrenergic 
i.e. activated by noradrenaline or some other endogenous neurotransmitter. Hence, this 
pattern of inhibition indicated a greater contribution of α1-adrenoceptors (versus α2-
adrenoceptors) in sympathetic-mediated contractions in blood vessels of animals with chronic 
inflammation compared to controls. 
The small residual contractions in the presence of WB4101 and prazosin could be 
indicative of the action of other neurotransmitters released from sympathetic nerves other 
than noradrenaline, e.g. adenosine triphosphate and neuropeptide Y. Purinergic receptors have 
been identified in vascular smooth muscle cells and play an important role in physiological 
responses (Harhun et al., 2015). Interestingly, electrical field-stimulation also evoke the release 
of adenosine triphosphate (ATP) from sympathetic nerve terminals (Bao and Stjarne, 1993; Bao 
et al., 1993). Hence, the observed contractions are presumably the result of the dual contractile 
effects of NA and ATP through the activation of adrenergic and purinergic receptors, 
respectively. However, Bao and Stjarne (1993) demonstrated that P2x receptor activation only 
contributes to the initial rapid phase in neurogenic contraction. Still, the possible effect of 
inflammation on ATP-mediated purinergic activation remains unknown. 
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In the present study, cocaine significantly enhanced electric field evoked contractions in 
the frequency stimulation range between 5 and 20 Hz. The potentiating action of cocaine on 
sympathetic nerve-mediated contractions has been attributed to the inhibition of 
neurotransmitter reuptake (Bao et al., 1993; Duggan et al., 2011). By inhibiting the reuptake of 
noradrenaline from the “synaptic cleft”, cocaine causes a prolonged effect of noradrenaline on 
the post-synaptic alpha-adrenoceptors and enhances nerve-mediated contractions. Duggan et 
al. (2011) demonstrated potentiation of responses in rat pulmonary arteries to cocaine, as did 
Docherty (2014), who showed an increase in noradrenaline potency in rat vas deferens 
stimulated to exogenous noradrenaline in the presence of cocaine. This finding suggests a 
prolonged activation of the post-synaptic receptors or the increased potency of receptors to 
noradrenaline. Previous studies have reported cocaine-enhanced responses at low (0.1 – 1.0 
Hz) but not high (2.0 – 16 Hz) frequency stimulations (Webb et al., 1980). This is at variance 
with the present findings and those of Stjӓrne et al. (1994) and Zacharia et al. (2004). However, 
in the current study, there were no apparent differences in the mechanisms of neuronal uptake 
in tail arteries from CFA-treated vs saline-treated rats which suggests that the observed 
differences in EFS-evoked contractions are not linked to the uptake of the noradrenergic 
transmitter.   
4.3. Immunofluorescence 
Alpha1 receptor expression in the tail vasculature of CFA-treated animals was different 
compared to saline-treated rats as characterized by immunofluorescence. In vascular tissue, α1 
adrenoceptors are predominantly found in smooth muscle cells (Skinner et al., 1994; Bylund et 
al., 1998; Garland et al., 2004; Zacharia et al., 2004; Tripathi et al., 2015). It is also known that 
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sympathetic activation of these α1-adrenoceptors mediates smooth muscle contraction in 
blood vessels. In the current study, α1 receptors were observed in vascular smooth muscle cells 
of CFA- and saline-treated rats. In the vascular endothelium of CFA-treated rats, expression of 
alpha1 receptors deviated from alpha1 characterization in previous studies of receptor 
localization in blood vessels. This unique expression of alpha1 in the endothelium could 
represent a difference in adrenoceptor expression in the caudal vasculature of inflamed rats. It 
is possible that the α1-adrenoceptor activation in the endothelium may have led to the 
activation of different intracellular signaling pathways or represent a modified role of 
endothelial cells in the excitation-contraction coupling mechanism of blood vessels. Release of 
vasodilatory agents from the endothelium of blood vessels mediates smooth muscle relaxation 
and vasodilation (Félétou and Vanhoutte, 2000; Vanhoutte, 2009). Previous studies suggest 
that sympathetic activation of adrenoceptors inhibits the release of nitric oxide from the 
vascular endothelium (Liao and Homey, 1993; Hijmering et al., 2005). Furthermore, Kamper et 
al. (2005) found that sympathetic activation of peripheral α1-adrenoceptors attenuates the 
nitric oxide-mediated vasodilation, suggesting an inhibition of NO by an α-adrenergic 
mechanism. It is therefore conceivable that the activity of α1-adrenoceptors in the vascular 
endothelium of blood vessels from CFA-treated animals could have contributed to greater 
contractions through inhibition of the vasodilatory mechanisms.  
 In intact tail arteries, immunofluorescence showed reduced expression of alpha2b-
receptors in the endothelium of blood vessels from CFA-treated rats compared to blood vessels 
from saline-treated rats. Alpha2b-adrenergic receptors are predominantly located in the 
endothelium of vascular tissues but not in the smooth muscle layer of rat tail arteries (McNeill 
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et al., 1999). Activation of post-junctional α2-adrenoceptors by exogenously applied 
noradrenaline mediate modest contraction and endothelium-dependent relaxation (Flavahan 
et al., 1984; Majmudar et al., 1999) of the vascular smooth muscle cells. A recent study by 
Thang et al. (2015) found that TNF-α and macrophage infiltration in vascular adventitia inhibits 
α2-AR function causing increased release of noradrenaline from sympathetic nerves. Laukova et 
al. (2010) showed a decrease in gene expression of α2-adrenergic receptors in stress situations, 
assessed by the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-18) in the spleen from 
rats. It is possible that TNF-α may have down-regulated the expression of α2 receptors in a 
similar fashion. The functional relevance of this difference in α2-adrenoceptors in the 
endothelium could reflect a disturbed vasodilatory response of α2-receptors activation in blood 
vessels from inflamed rats. However, this immunochemical difference in α2b-adrenoceptor 
expression was not reflected in our functional studies since α2-adrenoceptor antagonism had 
no effect on the electrical field-evoked contractions of blood vessels.  
4.4. Limitations to study 
 The present investigation did not quantify sympathetic noradrenaline release to 
compare SNS activation in blood vessels of inflamed versus non-inflamed animals. It also did 
not investigate the effect of a joint α1- and α2-adrenoceptor blockade on nerve-mediated 
contractions in the tail artery, whose joint action may further contribute to an altered signaling 
or contraction mechanism in blood vessels of inflamed or non-inflamed animals. 
 The administration of analgesic (buprenorphine) for pain management in the CFA-
treated animals could also present a limitation to the current study. 
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Furthermore, in the present study, the effect of inflammation on nerve-mediated 
vasoconstriction was examined in rat tail arteries in vitro. In vivo, the interplay between the 
immune system and CNS also determines how the inflammatory response influences the 
sympathetic nervous system and vascular function. Hence, our current data may underestimate 
the contribution of cytokines and the interplay between the inflammatory response and the 
sympathetic nerves could potentially have on the nerve-mediated physiological effects under in 
vivo conditions, as the effects of cytokines are short-lived. The question of whether the in vitro 
study directly translates in the in vivo state is unclear. 
 4.5. Future directions 
 The present study supported the hypothesis that various components of the neurogenic 
mediated vasoconstriction and vascular function are altered in tail arteries of inflamed animals. 
The findings also present evidence to suggest that the observed changes in vascular function 
are mediated chiefly by α1-adrenoceptor activation and distribution in animals attained by 
chronic inflammation. The findings of the present study are important in understanding the 
pathophysiology of vascular diseases mediated by chronic inflammation, for example, 
atherosclerosis. 
 It would be interesting to test whether the simultaneous effects of prazosin and 
rauwolscine in the vascular smooth muscle function of inflamed and non-inflamed rats compare 
to the effects of WB4101. In addition, to compare the effects of prazosin on EFS-induced 
contractions in blood vessels of inflamed and non-inflamed rats in the presence of cocaine. 
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There is speculation that increased systemic levels of TNF-α could induce smooth 
muscle contractions through sympathetic activation of adrenoceptors or other transduction 
pathways that contribute to vascular smooth muscle contractions. This concept is supported by 
the presence of adrenoceptors on immune system organs and the bidirectional relationship 
between the immune system and the central nervous system in modulating the inflammatory 
response. Hence, future studies investigating the direct effect of exogenously applied cytokines 
(e.g. TNF-α or IL-6) on the neurogenic contractions in tail arteries of rats would provide more 
understanding on the contribution of circulating cytokines in vivo on sympathetic nerve and 
vascular function in persons afflicted with chronic inflammation.    
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6.0. Appendix 
Table AI: Pharmacological treatment groups for electric field-evoked contraction studies of tail arteries from CFA-treated and saline-treated animals. 
Frequency Response Curve 
Drug 
Drug 1 (M) Drug 2 (M) 
Deionized water (Vehicle) 20 µl 60 µl 
Prazosin Prazosin: 10-7 Prazosin: 3x10-7 
Rauwolscine Rauwolscine: 10-6 Rauwolscine: 3x10-6 
WB4101 WB4101: 10-8 WB4101: 3x10-8 
Cocaine + Deionized water Cocaine: 10-6 Deionized water: 60 µl 
Cocaine + Rauwolscine Cocaine: 10-6 Rauwolscine: 3x10-6 
Cocaine + WB4101 Cocaine: 10-6 WB4101: 3x10-8 
 
  




Figure AI: Effect of tetrodotoxin on field stimulation-evoked contractions at 50 V and 0.5 ms 
pulse in tail arteries of saline-treated (A) and CFA-treated (B) rats at the frequency indicated.  
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Figure AII: Representative tracing of the effect of prazosin on the field stimulation-evoked 
contractions at 50 V and 0.5 ms pulse width in tail arteries of CFA-treated (A) and saline-treated  
(B) rats at frequencies indicated. 
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Figure AIII: Representative tracing of the effect of rauwoslcine on the field stimulation-evoked 
contractions in tail arteries of CFA-treated (A) and saline-treated (B) rats at frequencies indicated. 
